Achieved strong third quarter financial performance and increased full year 2018 guidance Acquired AMAG-423 for severe preeclampsia, reaffirming the company’s focus on delivering innovative therapies that address unmet medical needs Conference call scheduled for 8:00 a.m. ET today WALTHAM, MA (November 1, 2018) – AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today reported unaudited consolidated financial results for… More

  WALTHAM, Mass., October 25, 2018 –  AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that its third quarter 2018 financial results will be released on Thursday, November 1, 2018 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update… More

Study Suggests that While All Postmenopausal Women Benefit from Treatment with Prasterone (INTRAROSA®), Women Experience Greatest Relief of Moderate to Severe Dyspareunia when started on INTRAROSA® within One to Two Years after Menopause   WALTHAM, Mass. and QUEBEC CITY, Quebec, Oct. 04, 2018 (GLOBE NEWSWIRE) — AMAG Pharmaceuticals, Inc.(NASDAQ:AMAG) and Endoceutics today announced an oral presentation regarding the effect of time since menopause, age, and… More

Currently no FDA-approved treatment options for severe preeclampsia, a leading cause of maternal and neonatal mortality Acquisition expands AMAG’s maternal health portfolio and commitment to innovative therapies that address unmet medical needs Conference call scheduled today at 8:00 a.m. ET WALTHAM, Mass., September 26, 2018 — AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced it has acquired… More

Campaign Seeks to Help Women Recognize this Condition and Empower Them to Talk to Their Healthcare Providers about Treatment Options WALTHAM, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) — AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that together with Emmy®-nominated actress Cheryl Hines and leading family medicine and menopause expert, Marla Shapiro, MD, it is launching an integrated campaign to start an open… More

Early Retirement of more than $800 million in debt since mid-2017 significantly strengthens balance sheet WALTHAM, Mass., Sept. 06, 2018 (GLOBE NEWSWIRE) — AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that it has redeemed $475 million of its outstanding 7.875% senior notes, using the proceeds from the sale of Cord Blood Registry®, which closed on August 6,… More

WALTHAM, Mass., Aug. 23, 2018 (GLOBE NEWSWIRE) — AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that company management will participate in the following investor conferences: B. Riley FBR Healthcare Conference Tuesday, September 4, 2018 (one-on-one meetings only) Location: New York, NY Wells Fargo Healthcare Conference Wednesday, September 5, 2018 at 1:50 p.m. ET* Location: Boston,… More

WALTHAM, Mass., Aug. 06, 2018 (GLOBE NEWSWIRE) — AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced it has closed the previously announced divestiture of Cord Blood Registry (CBR®) to GI Partners, a private equity investment firm, for $530 million in an all cash sale. The purchase price is subject to customary purchase price adjustments with respect to working… More

WALTHAM, Mass., Aug. 06, 2018 (GLOBE NEWSWIRE) — AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced the appointment of Brian Robinson, M.D. as senior vice president, medical affairs, reporting into Julie Krop, M.D., chief medical officer and executive vice president, development. In collaboration with Dr. Krop, he will oversee the medical affairs strategy for the company’s innovative… More

Achieved 12% revenue growth and record quarterly sales Raising full year revenue and adjusted EBITDA guidance for pharmaceutical products Conference call scheduled for 8:00 a.m. ET today WALTHAM, Mass., Aug. 02, 2018 (GLOBE NEWSWIRE) — AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today reported unaudited consolidated financial results for the quarter ended June 30, 2018. The company announced… More